ID   NZM005
AC   CVCL_D837
SY   NZM05; NZM5
DR   BioSample; SAMN07624449
DR   BioSample; SAMN14558316
DR   cancercelllines; CVCL_D837
DR   CBA; CBA-1388
DR   Cosmic; 2007646
DR   Wikidata; Q54931584
RX   CelloPub=CLPUB00227;
RX   PubMed=7718330;
RX   PubMed=7999427;
RX   PubMed=11216673;
RX   PubMed=20041153;
RX   PubMed=23658559;
RX   PubMed=32567790;
CC   Doubling time: 30 hours (PubMed=7718330); 48 hours (CBA=CBA-1388).
CC   Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Heterozygous (PubMed=32567790).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Axillary lymph node; UBERON=UBERON_0001097.
ST   Source(s): CBA=CBA-1388; PubMed=32567790
ST   Amelogenin: X
ST   CSF1PO: 12,13
ST   D13S317: 12,13
ST   D16S539: 12,13
ST   D18S51: 15
ST   D19S433: 12,14 (PubMed=32567790)
ST   D19S433: 12,14,15 (CBA=CBA-1388)
ST   D21S11: 28,31.2
ST   D2S1338: 17,26
ST   D3S1358: 15
ST   D5S818: 11,12
ST   D7S820: 10
ST   D8S1179: 9,13
ST   FGA: 21,23
ST   TH01: 6,9.3
ST   TPOX: 9,11
ST   vWA: 16
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   79Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 19-12-24; Version: 19
//
RX   CelloPub=CLPUB00227;
RA   Daukste L.;
RT   "Mathematical modelling of cancer cell population dynamics.";
RL   Thesis PhD (2012); University of Canterbury; Christchurch; New Zealand.
//
RX   PubMed=7718330; DOI=10.1016/0959-8049(94)00472-H;
RA   Baguley B.C., Marshall E.S., Whittaker J.R., Dotchin M.C., Nixon J.,
RA   McCrystal M.R., Finlay G.J., Matthews J.H.L., Holdaway K.M.,
RA   van Zijl P.L.;
RT   "Resistance mechanisms determining the in vitro sensitivity to
RT   paclitaxel of tumour cells cultured from patients with ovarian
RT   cancer.";
RL   Eur. J. Cancer 31A:230-237(1995).
//
RX   PubMed=7999427; DOI=10.1016/0959-8049(94)90188-0;
RA   Marshall E.S., Matthews J.H.L., Shaw J.H.F., Nixon J., Tumewu P.,
RA   Finlay G.J., Holdaway K.M., Baguley B.C.;
RT   "Radiosensitivity of new and established human melanoma cell lines:
RT   comparison of [3H]thymidine incorporation and soft agar clonogenic
RT   assays.";
RL   Eur. J. Cancer 30A:1370-1376(1994).
//
RX   PubMed=11216673; DOI=10.3727/096504001108747620;
RA   Parmar J., Marshall E.S., Charters G.A., Holdaway K.M., Shelling A.N.,
RA   Baguley B.C.;
RT   "Radiation-induced cell cycle delays and p53 status of early passage
RT   melanoma cell lines.";
RL   Oncol. Res. 12:149-155(2000).
//
RX   PubMed=20041153; DOI=10.1371/journal.pone.0008461; PMCID=PMC2794539;
RA   Jeffs A.R., Glover A.C., Slobbe L.J., Wang L., He S.-J., Hazlett J.A.,
RA   Awasthi A., Woolley A.G., Marshall E.S., Joseph W.R., Print C.G.,
RA   Baguley B.C., Eccles M.R.;
RT   "A gene expression signature of invasive potential in metastatic
RT   melanoma cells.";
RL   PLoS ONE 4:E8461-E8461(2009).
//
RX   PubMed=23658559; DOI=10.3389/fgene.2013.00066; PMCID=PMC3647113;
RA   Stones C.J., Kim J.E., Joseph W.R., Leung E.Y., Marshall E.S.,
RA   Finlay G.J., Shelling A.N., Baguley B.C.;
RT   "Comparison of responses of human melanoma cell lines to MEK and BRAF
RT   inhibitors.";
RL   Front. Genet. 4:66.1-66.6(2013).
//
RX   PubMed=32567790; DOI=10.1111/pcmr.12908; PMCID=PMC7818249;
RA   Tran K.B., Gimenez G., Tsai P., Kolekar S., Rodger E.J.,
RA   Chatterjee A., Jabed A., Shih J.-H., Joseph W.R., Marshall E.S.,
RA   Wang Q., Print C.G., Eccles M.R., Baguley B.C., Shepherd P.R.;
RT   "Genomic and signalling pathway characterization of the NZM panel of
RT   melanoma cell lines: a valuable model for studying the impact of
RT   genetic diversity in melanoma.";
RL   Pigment Cell Melanoma Res. 34:136-143(2021).
//